TISIDB

Summary
Symbol	CAT
Name	catalase
Aliases
Chromosomal Location	11p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Peroxisome.
Domain	PF00199 Catalase PF06628 Catalase-related immune-responsive
Function	Occurs in almost all aerobically respiring organisms and serves to protect cells from the toxic effects of hydrogen peroxide. Promotes growth of cells including T-cells, B-cells, myeloid leukemia cells, melanoma cells, mastocytoma cells and normal and transformed fibroblast cells.

> Gene Ontology [ TOP ]
Biological Process	GO:0000302 response to reactive oxygen species GO:0001101 response to acid chemical GO:0001503 ossification GO:0001649 osteoblast differentiation GO:0001655 urogenital system development GO:0001657 ureteric bud development GO:0001666 response to hypoxia GO:0001822 kidney development GO:0001823 mesonephros development GO:0006066 alcohol metabolic process GO:0006091 generation of precursor metabolites and energy GO:0006195 purine nucleotide catabolic process GO:0006638 neutral lipid metabolic process GO:0006639 acylglycerol metabolic process GO:0006641 triglyceride metabolic process GO:0006979 response to oxidative stress GO:0007568 aging GO:0007584 response to nutrient GO:0008202 steroid metabolic process GO:0008203 cholesterol metabolic process GO:0009060 aerobic respiration GO:0009166 nucleotide catabolic process GO:0009314 response to radiation GO:0009411 response to UV GO:0009416 response to light stimulus GO:0009636 response to toxic substance GO:0009642 response to light intensity GO:0009650 UV protection GO:0009743 response to carbohydrate GO:0009991 response to extracellular stimulus GO:0010035 response to inorganic substance GO:0010038 response to metal ion GO:0010193 response to ozone GO:0010288 response to lead ion GO:0014065 phosphatidylinositol 3-kinase signaling GO:0014066 regulation of phosphatidylinositol 3-kinase signaling GO:0014068 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014823 response to activity GO:0014854 response to inactivity GO:0015980 energy derivation by oxidation of organic compounds GO:0016125 sterol metabolic process GO:0019439 aromatic compound catabolic process GO:0020027 hemoglobin metabolic process GO:0031667 response to nutrient levels GO:0032088 negative regulation of NF-kappaB transcription factor activity GO:0032355 response to estradiol GO:0032868 response to insulin GO:0033189 response to vitamin A GO:0033197 response to vitamin E GO:0033273 response to vitamin GO:0033591 response to L-ascorbic acid GO:0034284 response to monosaccharide GO:0034655 nucleobase-containing compound catabolic process GO:0036293 response to decreased oxygen levels GO:0036296 response to increased oxygen levels GO:0042493 response to drug GO:0042542 response to hydrogen peroxide GO:0042743 hydrogen peroxide metabolic process GO:0042744 hydrogen peroxide catabolic process GO:0043433 negative regulation of sequence-specific DNA binding transcription factor activity GO:0043434 response to peptide hormone GO:0044270 cellular nitrogen compound catabolic process GO:0045333 cellular respiration GO:0045471 response to ethanol GO:0046434 organophosphate catabolic process GO:0046486 glycerolipid metabolic process GO:0046686 response to cadmium ion GO:0046700 heterocycle catabolic process GO:0048015 phosphatidylinositol-mediated signaling GO:0048017 inositol lipid-mediated signaling GO:0051090 regulation of sequence-specific DNA binding transcription factor activity GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051092 positive regulation of NF-kappaB transcription factor activity GO:0051259 protein oligomerization GO:0051260 protein homooligomerization GO:0051262 protein tetramerization GO:0051289 protein homotetramerization GO:0051302 regulation of cell division GO:0051781 positive regulation of cell division GO:0055093 response to hyperoxia GO:0070482 response to oxygen levels GO:0070542 response to fatty acid GO:0072001 renal system development GO:0072073 kidney epithelium development GO:0072163 mesonephric epithelium development GO:0072164 mesonephric tubule development GO:0072523 purine-containing compound catabolic process GO:0072593 reactive oxygen species metabolic process GO:0080184 response to phenylpropanoid GO:0097305 response to alcohol GO:0098754 detoxification GO:0098869 cellular oxidant detoxification GO:1901292 nucleoside phosphate catabolic process GO:1901361 organic cyclic compound catabolic process GO:1901565 organonitrogen compound catabolic process GO:1901615 organic hydroxy compound metabolic process GO:1901652 response to peptide GO:1902652 secondary alcohol metabolic process GO:1990748 cellular detoxification
Molecular Function	GO:0004046 aminoacylase activity GO:0004096 catalase activity GO:0004601 peroxidase activity GO:0016209 antioxidant activity GO:0016684 oxidoreductase activity, acting on peroxide as acceptor GO:0016810 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds GO:0016811 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amides GO:0020037 heme binding GO:0046906 tetrapyrrole binding GO:0048037 cofactor binding GO:0050661 NADP binding GO:0050662 coenzyme binding
Cellular Component	GO:0005758 mitochondrial intermembrane space GO:0005777 peroxisome GO:0005778 peroxisomal membrane GO:0005782 peroxisomal matrix GO:0005924 cell-substrate adherens junction GO:0005925 focal adhesion GO:0030055 cell-substrate junction GO:0031903 microbody membrane GO:0031907 microbody lumen GO:0031970 organelle envelope lumen GO:0042579 microbody GO:0044438 microbody part GO:0044439 peroxisomal part

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04068 FoxO signaling pathway hsa04146 Peroxisome hsa00380 Tryptophan metabolism hsa00630 Glyoxylate and dicarboxylate metabolism hsa01200 Carbon metabolism
Reactome	R-HSA-2262752: Cellular responses to stress R-HSA-3299685: Detoxification of Reactive Oxygen Species R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-1430728: Metabolism R-HSA-15869: Metabolism of nucleotides R-HSA-6798695: Neutrophil degranulation R-HSA-74259: Purine catabolism R-HSA-73847: Purine metabolism

Summary
Symbol	CAT
Name	catalase
Aliases
Chromosomal Location	11p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between CAT and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	CAT
Name	catalase
Aliases
Chromosomal Location	11p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of CAT in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	Total # shRNA with >= 4-fold: 1	Resistant to T-cell proliferation
24476824	shRNA	melanoma	B16	Secondary screen	Total # shRNA with >= 4-fold: 1	Resistant to T-cell proliferation

Summary
Symbol	CAT
Name	catalase
Aliases
Chromosomal Location	11p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of CAT in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.488	0.23
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	1.008	0.667
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.11	0.949
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.012	0.981
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.771	0.676
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.949	0.686
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.023	0.959
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.434	0.817
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.46	0.829
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.042	0.983
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.365	0.905
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.003	0.973

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of CAT in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	11.1	2.7	8.4	0.12
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	11.1	3.4	7.7	0.176
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	11.8	-11.8	0.193
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	18.2	-18.2	0.199
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	CAT
Name	catalase
Aliases
Chromosomal Location	11p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CAT. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	CAT
Name	catalase
Aliases
Chromosomal Location	11p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CAT. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CAT. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	CAT
Name	catalase
Aliases
Chromosomal Location	11p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CAT. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	CAT
Name	catalase
Aliases
Chromosomal Location	11p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of CAT expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	CAT
Name	catalase
Aliases
Chromosomal Location	11p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between CAT and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	CAT
Name	catalase
Aliases
Chromosomal Location	11p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting CAT collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting CAT.

ID	Name	Drug Type	Targets	#Targets
DB01213	Fomepizole	Small Molecule	ADH1A, ADH1B, ADH1C, CAT	4

Browse CAT